PMID: 15228660Jul 2, 2004Paper

Expression and clinical significance of lymphoid differentiation antigens in acute myeloid leukemia

Zhongguo shi yan xue ye xue za zhi
Xing-Hong Guo, Dan Ni

Abstract

The present study was aimed to elucidate the expression features of lymphoid differentiation antigens and their clinical implications in acute myeloid leukemia (AML). Immunophenotypes were examined by indirect immunofluorescence method with monoclonal antibodies (McAb) in 62 patients with AML. The results showed that 11 cases of AML were found to express lymphoid differentiation antigen Ly(+)AML in addition to myeloid antigen expression. There was no significant difference in clinical manifestation and blood test between the groups of Ly(+)AML and Ly(-)AML when they were newly diagnosed. Only one case gained long-term remission using standard chemotherapy. It is concluded that Ly(+)AML cells seem to be not sensitive to conventional chemotherapy, however, a treatment protocol for both ALL and AML can improve the curative effects. The overexpression of CD34(+) may be responsible for the relatively low level of long term survival rate in Ly(+)AML patients.

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.